-
New medication for the treatment of advanced pancreatic cancer increases median overall survival from 6.7 to 13.2 months.
Medical Mythbusting Commentary for June 1, 2026 Source:‘I actually started crying’: Oncologist reacts to pancreatic cancer drug results Synopsis of the article and study: Benefits: Doubled survival, oral convenience, targeted action, manageable side effects. Limitations: Grade 3+ adverse events in about one-third of patients; still experimental, not yet fully approved; tested in advanced cases post-chemo.
-
Mouse model demonstrates that using microRNA via nasal spray reverses some of the inflammatory processes that contribute to brain aging and cognitive decline. Many years to go to determine if safe and efficacious for people.
Medical Mythbusting Commentary for May 28, 2026 Source:Scientists say they’ve reversed brain aging with a simple nasal spray Reference: Intranasal Human NSC‐Derived EVs Therapy Can Restrain Inflammatory Microglial Transcriptome, and NLRP3 and cGAS‐STING Signalling, in Aged Hippocampus
-
Beta-blockers, taken by millions after a heart attack, found to be ineffective for people with uncomplicated heart attacks (normal heart function thereafter) and presents increased risk of harm to women. Changes to management likely in the works for this population.
Medical Mythbusting Commentary for May 27, 2026 Source:Common heart drug taken by millions found useless — and possibly dangerous Reference:Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction Beta-blockers after myocardial infarction: effects according to sex in the REBOOT trial
-
Remnant cholesterol levels found to be an independent risk factor for heart disease. We discuss what this is and what the approach to management entails.
Medical Mythbusting Commentary for May 26, 2026 Source:Experts have found a new type of cholesterol. And it could be the most dangerous Reference: Source: openevidence.comRemnant cholesterol — defined as total cholesterol minus LDL-C minus HDL-C — is an emerging and increasingly recognized causal risk factor for ASCVD. Management centers on lifestyle modification as first-line therapy,…
-
Observational study noted that patients with diabetes and obesity using GLP-1 medications may experience reduced degree of metastases. Causality confirmation and mechanisms to be determined.
Medical Mythbusting Commentary for May 25, 2026 Source:GLP-1 Users May Experience A Surprising Life-Saving Benefit That Has Nothing To Do With Weight Loss
-
Human limb regeneration still a long way away. However the gene responsible for this function has been isolated in other animal models.
Medical Mythbusting Commentary for May 11, 2026 Source:Scientists found the “holy grail” gene that could one day help humans regrow limbs Reference:Enhancer-directed gene delivery for digit regeneration based on conserved epidermal factors.
-
Unexpected hormone discovery of GLP-1 in joints may provide new avenues for arthritis treatment once it is determined what it is actually doing in the joint. Lots of work ahead.
Medical Mythbusting Commentary for April 30, 2026 Source:Unexpected Hormone Discovery Could Change How We Treat Arthritis Reference:Detection of GLP-1 and DPP-4 in synovial fluid: implications for therapeutical strategies in arthritis
-
Researchers are working on blood tests that may provide early detection of potential Alzheimer’s disease later in life.
Medical Mythbusting Commentary for April 22, 2026 Source:Blood Tests Could Reveal Alzheimer’s Risk Years Before Symptoms Appear Reference:Plasma phosphorylated tau 217 and longitudinal trajectories of Aβ, tau, and cognition in cognitively unimpaired older adults
-
Large observational study finds correlation between prenatal cholesterol-disrupting meds and higher autism rates; causation not proven.
Medical Mythbusting Commentary for April 21, 2026 Source:Millions of US birth records uncover an autism risk surge tied to common drugs taken during pregnancy Reference:Sterol pathway disruption in pregnancy: a link to autism